Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + delta-9-tetrahydrocannabinol
- Development stage
- Unknown
- Lead developer
- New York State Psychiatric Hospital
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
This specific formulation of smoked cannabis is characterized by a high concentration of cannabidiol (CBD, 15.76%) and a low concentration of delta-9-tetrahydrocannabinol (THC, 3.11%). Developed for clinical investigation by the New York State Psychiatric Institute, it is primarily studied for the management of chronic pain and symptoms in palliative care patients. The formulation is designed to leverage the potent anti-inflammatory and analgesic properties of CBD while minimizing the psychoactive and intoxicating effects typically associated with high-THC cannabis strains. Its therapeutic effect is mediated through the modulation of the endocannabinoid system, where THC acts as a partial agonist at CB1 and CB2 receptors, and CBD acts as a negative allosteric modulator of these receptors while also engaging TRPV1 and 5-HT1A pathways.
- Other names
- Smoked Cannabis High CBD/low THC15.76% CBD; 3.11% THC cannabisHigh CBD/low THC cannabis
02
Targets
CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on cannabidiol + delta-9-tetrahydrocannabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + delta-9-tetrahydrocannabinol.